We are live on ! Find out more
ARQT icon

Arcutis Biotherapeutics
ARQT

63 hedge funds and large institutions have $1.02B invested in Arcutis Biotherapeutics in 2020 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 31 increasing their positions, 10 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

210% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 10

175% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 4

13% more funds holding

Funds holding: 56 → 63 (+7)

2.52% more ownership

Funds ownership: 88.51% → 91.03% (+2.5%)

0% less capital invested

Capital invested by funds: $1.02B → $1.02B (-$3.69M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
63
Holders Change
+7
Holders Change %
+12.5%
% of All Funds
1.27%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.06%
New
11
Increased
31
Reduced
10
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$13.1M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$12.8M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.56M
4
Northern Trust
Northern Trust
Illinois
+$2.19M
5
State Street
State Street
Massachusetts
+$2.11M

Top Sellers

Rank Fund Capital Flow
1
OFM
Omega Fund Management
Massachusetts
-$4.96M
2
VC
Vivo Capital
California
-$4.7M
3
PC
Polar Capital
United Kingdom
-$2.67M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$2.02M
5
Renaissance Technologies
Renaissance Technologies
New York
-$838K
Name Holding Trade Value Shares
Change 		Change in
Stake
FM
1
Frazier Management
Washington
$309M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$168M +$139K +5,211 +0.1%
O
3
OrbiMed
New York
$137M – – –
BCLSI
4
Bain Capital Life Sciences Investors
Massachusetts
$117M – – –
BlackRock
5
BlackRock
New York
$60.3M +$13.1M +489,812 +31%
RCM
6
RA Capital Management
Massachusetts
$34.1M – – –
VC
7
Vivo Capital
California
$32.6M -$4.7M -176,095 -14%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$29M -$2.02M -75,519 -7%
Vanguard Group
9
Vanguard Group
Pennsylvania
$25.1M +$12.8M +479,585 +127%
OFM
10
Omega Fund Management
Massachusetts
$19.3M -$4.96M -185,772 -22%
Wells Fargo
11
Wells Fargo
California
$16.3M +$781K +29,236 +6%
PC
12
Polar Capital
United Kingdom
$10.3M -$2.67M -100,000 -22%
Ameriprise
13
Ameriprise
Minnesota
$8.33M +$172K +6,427 +2%
State Street
14
State Street
Massachusetts
$7.78M +$2.11M +78,854 +42%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$7.26M +$2.56M +95,651 +63%
Northern Trust
16
Northern Trust
Illinois
$6.16M +$2.19M +81,938 +64%
Goldman Sachs
17
Goldman Sachs
New York
$5.26M +$199K +7,462 +4%
Charles Schwab
18
Charles Schwab
California
$3.24M +$1.13M +42,377 +62%
AllianceBernstein
19
AllianceBernstein
Tennessee
$2.22M -$45.4K -1,700 -2%
N
20
Nuveen
North Carolina
$2M +$653K +24,425 +56%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$1.66M +$571K +21,356 +61%
LCM
22
Laurion Capital Management
New York
$1.47M – – –
AA
23
ALPS Advisors
Colorado
$1.43M -$89.7K -3,359 -6%
Point72 Asset Management
24
Point72 Asset Management
Connecticut
$1.27M +$1.16M +43,256 New
California Public Employees Retirement System
25
California Public Employees Retirement System
California
$1.2M +$531K +19,885 +95%
1
2 3

ARQT Hedge Fund Activity: Q3 2020 in Review

63 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q3 2020, worth a combined $1.02B — down 0.36% from $1.02B a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new ARQT positions and 4 closed out — a net gain of 7 holders — while 31 added to existing stakes and 10 trimmed.

The largest buyer was BlackRock, adding an estimated $13.1M. The largest seller was Omega Fund Management, cutting an estimated $4.96M.

  • 63 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q3 2020, up from 56 in Q2 2020.
  • Funds reported $1.02B of Arcutis Biotherapeutics stock for Q3 2020, down 0.36% quarter-over-quarter.
  • 11 funds opened new Arcutis Biotherapeutics positions in Q3 2020 and 4 closed out, a net change of +7 holders.
  • The largest Arcutis Biotherapeutics buyer in Q3 2020 was BlackRock, an estimated $13.1M added.
  • The largest Arcutis Biotherapeutics seller in Q3 2020 was Omega Fund Management, an estimated $4.96M sold.

Based on aggregated 13F filings for Q3 2020.